Valsartan/Hydrochlorothiazide Tablets
Key Dates
Due Date
-
Posted Date
-
Agency & Value
Agency
DLA TROOP SUPPORT
Contract Value
Not provided
Codes & Classification
Solicitation Number
SPE2D2-25-R-0014
NAICS
325412 - Pharmaceutical Preparation Manufacturing
Classification Code
6505
Additional Details
Documents1
The Defense Logistics Agency (DLA) Troop Support, a division of the Department of Defense, has issued a solicitation (Procurement Identifier: SPE2D2-25-R-0014) for the supply of Valsartan/Hydrochlorothiazide Tablets. This procurement falls under NAICS Code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code 6505, indicating a focus on drugs and biologicals.
The primary objective of this solicitation is to secure a reliable source of Valsartan/Hydrochlorothiazide Tablets, a combination medication commonly used in the management of hypertension. The intended outcome is to ensure the consistent availability of this essential pharmaceutical product to support the health and readiness of military personnel and other authorized recipients. The scope of the procurement encompasses the manufacturing, packaging, and delivery of the specified tablets in accordance with the detailed requirements outlined in the attached solicitation document.
Key requirements for this opportunity include compliance with all applicable federal regulations governing pharmaceutical manufacturing, as well as adherence to the quality standards and specifications set forth by the DLA Troop Support. Offerors are expected to demonstrate their capability to produce and supply pharmaceutical-grade Valsartan/Hydrochlorothiazide Tablets, ensuring product efficacy, safety, and timely delivery. The solicitation may also specify packaging, labeling, and shipping requirements to facilitate efficient distribution within the Department of Defense supply chain.
The contracting activity is managed by DLA Troop Support, a federal office within the Defense Logistics Agency. Interested parties may direct inquiries to the primary contact, Kyle Lewicki ([email protected], 445-737-0977), or the secondary contact, Jason Wray ([email protected], 445-737-6304), for further information regarding the solicitation or submission process.
This procurement is being conducted as a formal solicitation, and all interested contractors are encouraged to review the attached solicitation document for comprehensive details on submission requirements, evaluation criteria, and contract terms. The notice is currently active, with a response deadline set for August 13, 2026, at 19:08. Contractors specializing in pharmaceutical preparation manufacturing who possess the requisite capabilities and compliance certifications are well-positioned to participate in this opportunity.
For additional information and to access the solicitation attachment, interested parties should refer to the official notice on SAM.gov (Opportunity ID: 88c763e4b56e4e20b26966dc629e9cf0) at the following URL: https://sam.gov/opp/88c763e4b56e4e20b26966dc629e9cf0/view.
This procurement represents a significant opportunity for qualified pharmaceutical manufacturers to support the Department of Defense’s mission by ensuring the availability of critical medications. Contractors are advised to carefully review all solicitation materials and direct any questions to the designated contacts to ensure a complete and compliant response.